N/A
N=35
Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Bottom Line
View on ClinicalTrials.gov: NCT03646643 ↗Enrolled (actual)
35
Serious AEs
3.3%
Results posted
Nov 2024
Primary outcome: Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Standard Atrial fibrillation ablation (Procedure); Coronary sinus to left atrium connection elimination (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Pennsylvania
- Primary completion
- Nov 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Recurrence Rate of Atrial Arrhythmias |
8; 14; 7; 1 | 0.047 sig |
Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people in the US and around the world. Over the last 20 years, catheter based AF ablation has been widely adopted offering improved symptom control for many patients worldwide. However, long-term success rates remain suboptimal. Prior work indicates that distal connections between coronary sinus musculature and the left atrium exist and provide a substrate for single or multiple reentry beats as a trigger for atrial fibrillation. In this trial, the investigators will examine the efficacy of elimination of distal connection(s) between coronary sinus and left atrial musculature for suppression of recurrent atrial arrhythmias.
Eligibility Criteria
Inclusion Criteria
- Patients with paroxysmal or persistent atrial fibrillation; AND Undergoing first AF ablation; AND Age ≥ 18 years.
Exclusion Criteria
- Previous left atrial ablation; Women currently pregnant; Mental or physical inability to take part in the study; Known terminally ill patients.
Data sourced from ClinicalTrials.gov (NCT03646643). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.